الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
The present study included 50 UBC cases randomly selected from the archive of histopathological laboratories of Minia Oncology Center including 35 UCB cases and 15 SCC cases.
TRIP13 expression scoring ranges between –ve/low and high. Thirty one cases (62%) showed –ve/low expression while 19 cases (38%) showed high expression. Significant association was found between TRIP13 expression and tumour grade, tumour stage, presence of lymph node metastases and distant metastasis (p= 0.012, 0.007, <0.001 and 0.004 respectively). High TRIP13 expression was significantly associated with poor OS and DFS in univariate analysis (p= 0.011 and 0.010 respectively). On multivariate regression analysis, high TRIP13 expression was independently significantly associated with short DFS (p= 0.013).
Our results strongly suggest that UBC patients whose tumour exhibit high TRIP13 immunoexpression, have increased risk of cancer progression, poor prognostic features and poor prognosis in comparison to patients whose tumors express –ve/low expression scores.
Conclusion
The current study reported significant associations between high TRIP13 expression and poor prognostic features.
The present study highlighted the important role of TRIP13 as a poor prognostic biomarker in urinary bladder cancer cases.